Antigen-presenting cells transduced by viral or DNA vector

Antigen-presenting cells (APCs) transduced by viral or DNA vectors represent a therapeutic modality rather than a specific molecular target. This approach involves the genetic modification of cells, most commonly dendritic cells, to express specific antigens such as tumor-associated antigens or viral proteins (National Cancer Institute, 2024). Viral vectors, such as adenovirus or lentivirus, or DNA plasmids are used to deliver genetic material into the APCs, which then process the encoded proteins and present them on their surface via major histocompatibility complex (MHC) molecules (Brossart et al., 2001, PubMed). This presentation is crucial for the activation of naive T-cells, leading to a robust and specific immune response against cells expressing those antigens (Arthur et al., 1997, Cancer Gene Therapy). While primarily investigated in oncology for cancer vaccines, this method is also explored for treating chronic infections. The primary therapeutic goal is to overcome immune tolerance and generate long-lasting immunological memory. However, challenges include the potential for vector-induced inflammatory responses and the technical complexity of ex vivo cell manipulation.

Other names

Transduced antigen-presenting cellsGenetically modified antigen-presenting cellsDendritic cell-based vaccinesViral vector-transduced APCsDNA-transduced APCsVector-modified APCs

Induction of antigen-specific T-cell immunity through the expression and MHC-mediated presentation of vector-encoded antigens.